US Stock MarketDetailed Quotes
ORGS Orgenesis
- 2.118
- +0.474+28.80%
15min DelayClose Dec 24 13:00 ET
10.95MMarket Cap-0.09P/E (TTM)
2.330High1.640Low17.44KVolume1.700Open1.644Pre Close32.75KTurnover0.38%Turnover RatioLossP/E (Static)5.17MShares10.79952wk High-0.46P/B9.77MFloat Cap0.87052wk Low--Dividend TTM4.61MShs Float168.000Historical High--Div YieldTTM41.97%Amplitude0.870Historical Low1.877Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
Orgenesis Stock Forum
Orgenesis: Nasdaq to Delist Co 's Common Stock, Securities Trading Will Be Suspended on Oct 21
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard.
On October 17, 2024, the Nasdaq Stock Market LLC (“Nasdaq”) notified Orgenesis Inc. (the “Company”) that the Nasdaq Hearings Panel (the “Panel”) has determined to delist the Company’s common stock and that trading of the Company’s securities will be suspended at the open of trading on October 21, 2024.
$CN Energy (CNEY.US)$ $Taoping (TAOP.US)$ $Alset (AEI.US)$ $Ambipar Emergency Response (AMBI.US)$ $Knightscope (KSCP.US)$ $Orgenesis (ORGS.US)$ $ShiftPixy (PIXY.US)$ $Aurora Mobile (JG.US)$ $CN Energy (CNEY.US)$
📊⚡️📊
Orgenesis Inc: Data Indicate a Potentially Favorable Safety Profile With a Lower Incidence of Cytokine Release Syndrome
Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic Leukemia
Orgenesis (NASDAQ: ORGS) announced positive results from a real-world study of its CD19 CAR-T therapy, ORG-101, in patients with CD19+ Acute Lymphoblastic Leukemia. The study showed complete response rates of 82% in adults and 93% in pediatric patients, with low incidence of severe Cytokine Release Syndrome (2% in adults, 6% in pediat...
No comment yet